Edition:
United States

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

7.09USD
2:57pm EDT
Change (% chg)

$-0.16 (-2.21%)
Prev Close
$7.25
Open
$7.23
Day's High
$7.24
Day's Low
$7.07
Volume
78,050
Avg. Vol
142,309
52-wk High
$9.69
52-wk Low
$3.11

Latest Key Developments (Source: Significant Developments)

Tetraphase Pharma Q1 loss per share $0.79
Thursday, 4 May 2017 04:05pm EDT 

May 4 (Reuters) - Tetraphase Pharmaceuticals Inc ::Tetraphase Pharmaceuticals reports first quarter 2017 financial results and reviews recent highlights.Q1 loss per share $0.79.Q1 revenue $1.5 million versus I/B/E/S view $1.5 million.Q1 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.Tetraphase Pharmaceuticals - "look forward to top-line data from ignite4 also in q3, which would support a subsequent U.S. NDA filing".  Full Article

Tetraphase Pharmaceuticals completes enrollment of ignite4 phase 3 clinical trial of eravacycline in complicated intra-abdominal infections
Monday, 3 Apr 2017 08:00am EDT 

Tetraphase Pharmaceuticals Inc : Tetraphase Pharmaceuticals completes enrollment of ignite4 phase 3 clinical trial of eravacycline in complicated intra-abdominal infections .Tetraphase Pharmaceuticals Inc says expects to report top-line data from ignite4 phase 3 clinical trial in Q3 of 2017.  Full Article

Tetraphase pharma Q4 loss per share $0.61
Wednesday, 8 Mar 2017 04:05pm EST 

Tetraphase Pharmaceuticals Inc : Tetraphase Pharmaceuticals reports fourth quarter and full-year 2016 financial results and highlights key 2017 milestones . Q4 loss per share $0.61 . Q4 earnings per share view $-0.60 -- Thomson Reuters I/B/E/S . Q4 revenue $1.1 million versus I/B/E/S view $1.4 million .Tetraphase Pharmaceuticals Inc - as of December 31, 2016, Tetraphase had cash and cash equivalents of $142.1 million and 36.9 million shares outstanding.  Full Article

Tetraphase Pharmaceuticals reports Q3 loss per share $0.58
Thursday, 3 Nov 2016 04:30pm EDT 

Tetraphase Pharmaceuticals Inc - : Tetraphase Pharmaceuticals reports third quarter 2016 financial results and reviews recent progress . Q3 loss per share $0.58 . Q3 revenue $900,000 versus $2.9 million . Q3 revenue view $1.6 million -- Thomson Reuters I/B/E/S .Q3 earnings per share view $-0.50 -- Thomson Reuters I/B/E/S.  Full Article

Tetraphase pharmaceuticals doses first patient in IGNITE4 phase 3 clinical trial of Eravacycline in cIAI
Friday, 14 Oct 2016 07:30am EDT 

Tetraphase Pharmaceuticals Inc : Tetraphase Pharmaceuticals doses first patient in IGNITE4 phase 3 clinical trial of eravacycline in cIAI . Tetraphase Pharmaceuticals Inc - top-line IGNITE4 data expected in 4Q 2017 .Tetraphase Pharmaceuticals Inc- study is expected to enroll approximately 450 adult patients.  Full Article

Tetraphase Pharmaceuticals reports Q2 loss per share $0.47
Thursday, 4 Aug 2016 04:52pm EDT 

Tetraphase Pharmaceuticals Inc : Q2 loss per share $0.47 . Q2 revenue view $2.1 million -- Thomson Reuters I/B/E/S . Tetraphase pharmaceuticals reports second quarter 2016 financial results and highlights recent progress . Q2 revenue $1.2 million versus $3.3 million . Q2 earnings per share view $-0.46 -- Thomson Reuters I/B/E/S .Cash, cash equivalents, expected revenue from u.s. Government awards, will be sufficient to fund operations into middle of 2018.  Full Article

More From Around the Web

BRIEF-Tetraphase Pharma Q1 loss per share $0.79

* Tetraphase Pharmaceuticals reports first quarter 2017 financial results and reviews recent highlights